These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27564257)

  • 1. New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.
    Lin SJ; Chou FJ; Lin CY; Chang HC; Yeh S; Chang C
    Oncotarget; 2016 Oct; 7(41):66769-66775. PubMed ID: 27564257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASC-J9
    Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
    Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib with ASC-J9
    Xu J; Lin H; Li G; Sun Y; Shi L; Ma WL; Chen J; Cai X; Chang C
    Int J Cancer; 2017 Feb; 140(3):705-717. PubMed ID: 27668844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor (AR) degradation enhancer ASC-J9
    Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
    Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
    J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting androgen receptor with ASC-J9 attenuates cardiac injury and dysfunction in experimental autoimmune myocarditis by reducing M1-like macrophage.
    Ma W; Wang Y; Lu S; Yan L; Hu F; Wang Z
    Biochem Biophys Res Commun; 2017 Apr; 485(4):746-752. PubMed ID: 28246012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
    Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
    Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
    Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
    Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.
    Soh SF; Huang CK; Lee SO; Xu D; Yeh S; Li J; Yong EL; Gong Y; Chang C
    J Pharm Biomed Anal; 2014 Jan; 88():117-22. PubMed ID: 24042123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
    Hu H; Zhou H; Xu D
    Chem Biol Drug Des; 2021 Apr; 97(4):821-835. PubMed ID: 33277796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis.
    Quick ML; Mukherjee S; Rudick CN; Done JD; Schaeffer AJ; Thumbikat P
    Am J Physiol Regul Integr Comp Physiol; 2012 Sep; 303(6):R580-9. PubMed ID: 22814670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells.
    Verderio P; Pandolfi L; Mazzucchelli S; Marinozzi MR; Vanna R; Gramatica F; Corsi F; Colombo M; Morasso C; Prosperi D
    Mol Pharm; 2014 Aug; 11(8):2864-75. PubMed ID: 24945469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CXCR3 on specific T cells is essential for homing to the prostate gland in an experimental model of chronic prostatitis/chronic pelvic pain syndrome.
    Breser ML; Motrich RD; Sanchez LR; Mackern-Oberti JP; Rivero VE
    J Immunol; 2013 Apr; 190(7):3121-33. PubMed ID: 23455510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9
    Izumi K; Chang C
    Oncoimmunology; 2013 Dec; 2(12):e26853. PubMed ID: 24498558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASC-J9 Blocks Cell Proliferation and Extracellular Matrix Production of Keloid Fibroblasts through Inhibiting STAT3 Signaling.
    Hong YK; Wu CH; Lin YC; Huang YL; Hung KS; Pai TP; Liu YT; Chen TC; Chan H; Hsu CK
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate.
    Shibuya S; Xia Z; Sugimoto M; Ueda N; Haba R; Kakehi Y
    Urology; 2014 Mar; 83(3):528-34. PubMed ID: 24581515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
    Said MM; Bosland MC
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.